Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is a specialty pharmaceutical company focused on identifying, developing and commercializing novel dermatologic treatments. Its lead drug candidate A-101 is entering late stage development for the treatment of seborrheic keratosis (SK), lesions, which are non-cancerous skin growths. Additionally, A-101 is entering into Phase 2 clinical trials for the treatment of common warts. Aclaris recently expanded its pipeline with the acquisition of a portfolio of Janus Kinase (JAK) inhibitor compounds for the treatment of alopecia areata and other dermatological conditions.